SEC Filing Analysis: SPRUCE BIOSCIENCES, INC. (SPRB)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director's out-of-the-money stock options were repriced to a lower exercise price, a common move to retain talent after a stock price decline.
• Market Impact: Neutral, as this is a non-cash compensation adjustment with no immediate market value.

Company Information

Field	Value
Company	SPRUCE BIOSCIENCES, INC.
Ticker Symbol	SPRB
CIK	0001683553
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	SPIEGELMAN DANIEL K
CIK	0001238403
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-12-11
Transaction Code	A / D (Acquisition/Disposition)
Security Type	Stock Option (Right to Buy)
Shares Involved	946
Price Per Share	$0.00
Total Value	$0
Shares Owned After	946 options
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0
% of Market Cap	0.00%
Shares Transacted	946 (options)
% of Shares Outstanding	Not Available
Post-Transaction Ownership	946 options
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a $110 million market cap, this non-cash, zero-value transaction has no direct financial impact.
• Ownership Concentration: The insider holds 946 options. Without shares outstanding data, the ownership percentage cannot be calculated, but the number of derivative securities is small.
• Dilution Impact: This is a modification of existing options, not a new grant. Therefore, it has no new dilutive impact on shareholders. The potential for future dilution upon exercise remains unchanged in terms of share count.
• Transaction Significance: The significance is Low from a direct trading perspective. The event's importance lies in what it signals about corporate governance and compensation strategy, indicating the board's effort to keep incentive compensation relevant for retention after a stock price decline.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The filing reports a non-cash, internal compensation adjustment. It does not represent new insider buying or selling on the open market and has no direct impact on the stock's float or market value.

Volume & Sentiment

• Expected Volume Impact: Negligible. This is not an open-market transaction and will not directly influence trading volume.
• Sentiment Indicator: Neutral. While some investors view option repricing as a negative signal about past performance, others see it as a necessary step to retain key personnel in a competitive industry.

Additional Context

Transaction Notes

• Special Circumstances: The filing documents a one-time stock option repricing. Existing options with exercise prices of $106.09 or greater were cancelled and re-issued with a new, lower exercise price of $104.13 (the 30-day VWAP). The number of shares and expiration dates of the options remain unchanged.